Is 7716 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 7716?
Other financial metrics that can be useful for relative valuation.
|What is 7716's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 7716's PE Ratio compare to its peers?
|7716 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
6849 Nihon Kohden
7817 Paramount Bed Holdings
6960 Fukuda Denshi
Price-To-Earnings vs Peers: 7716 is expensive based on its Price-To-Earnings Ratio (20.2x) compared to the peer average (12.7x).
Price to Earnings Ratio vs Industry
How does 7716's PE Ratio compare vs other companies in the JP Medical Equipment Industry?
Price-To-Earnings vs Industry: 7716 is expensive based on its Price-To-Earnings Ratio (20.2x) compared to the JP Medical Equipment industry average (14.5x)
Price to Earnings Ratio vs Fair Ratio
What is 7716's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||20.2x|
|Fair PE Ratio||20.9x|
Price-To-Earnings vs Fair Ratio: 7716 is good value based on its Price-To-Earnings Ratio (20.2x) compared to the estimated Fair Price-To-Earnings Ratio (20.9x).
Share Price vs Fair Value
What is the Fair Price of 7716 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 7716 (¥2713) is trading below our estimate of fair value (¥4538.7)
Significantly Below Fair Value: 7716 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.